On a roll, As­traZeneca flags loom­ing ap­provals for three big drug fran­chis­es

As­traZeneca cel­e­brat­ed a PR tri­fec­ta Mon­day morn­ing, nab­bing a pair of EU rec­om­men­da­tions for two of their lat­est block­busters along with a pri­or­i­ty re­view for a third from the FDA.

Their asth­ma fran­chise nabbed a thumbs-up from the CHMP for Tezspire as an add-on ther­a­py for those 12 and old­er not cur­rent­ly sta­bi­lized by any drug-cor­ti­cos­teroid treat­ment now on the mar­ket. And their C5 drug Ul­tomiris — the Soliris suc­ces­sor ac­quired in the Alex­ion buy­out — picked up a CHMP rec­om­men­da­tion for gen­er­al­ized myas­the­nia gravis pa­tients who are an­ti-acetyl­choline re­cep­tor an­ti­body-pos­i­tive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER